Dark

Check out our Dark Pool Levels

GLYC
GlycoMimetics, Inc.
stock NASDAQ

Inactive

Jun 13, 2025

15.70USD-5.422%(-0.90)10,694

Pre-market

0.00USD-100.000%(-16.60)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 14, 2021

07:36AM EST Glycomimetics Granted U.S. Patent #11,197,877 'Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists' Benzinga

Dec 13, 2021

09:37AM EST GlycoMimetics Highlights 2 Posters At ASH 2021 Meeting; Says Posters Highlight Potential Of GMI-1359, A Dual Antagonist Of CXCR4 And E-Selectin Benzinga

09:00AM EST Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin Business Wire

Dec 6, 2021

09:20AM EST GlycoMimetics Announces NIH And Alliance For Clinical Trials In Oncology Have Completed Enrollment Of 267 Patients In Phase 2 Portion Of Phase 2/3 Trial In Uproleselan Benzinga

09:15AM EST NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule Business Wire

Nov 24, 2021

08:00PM EST GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire

Nov 23, 2021

04:32PM EST Apollomics Inc. Doses First Patient In Phase 3 Clinical Trial In China of GlycoMimetics' Uproleselan For he Treatment oOf AML Benzinga

Nov 22, 2021

04:17PM EST GlycoMimetics Appoints Lisa DeLuca As VP, Regulatory Affairs RTTNews

04:15PM EST GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs Business Wire

Nov 15, 2021

10:53AM EST GlycoMimetics Completes Enrollment Of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan In Patients With Relapsed /Refractory Acute Myeloid Leukemia Benzinga

07:00AM EST GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML) Business Wire

Nov 12, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 12, 2021 Benzinga

05:40AM EST Jefferies Upgrades GlycoMimetics to Buy, Raises Price Target to $4 Benzinga

Nov 11, 2021

09:08AM EST GlycoMimetics Highlights GMI-1359 Data Selected For Presentation At American Society Of Hematology Meeting Dec. 11 And 13 Benzinga

09:00AM EST GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition Business Wire

Nov 9, 2021

09:00AM EST GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences Business Wire

Nov 2, 2021

10:52AM EDT GlycoMimetics Q3 EPS $(0.34) Misses $(0.32) Estimate Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

07:46AM EDT GlycoMimetics Q3 Loss/shr $0.34 Vs. Loss/shr $0.29/shr Prior Year RTTNews

07:30AM EDT GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021 Business Wire

Oct 26, 2021

09:00AM EDT GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021 Business Wire

Sep 27, 2021

10:04AM EDT GlycoMimetics Shares Up 1.9%; Roth Capital Reiterates Buy Rating; Sets $15 Price Target Benzinga

10:01AM EDT GlycoMimetics Shares Up 1.9%; Hearing Roth Capital Reiterates Buy Rating; Sets $15 Price Target Benzinga

09:24AM EDT Lena Napolitano-Sponsored Study Titled 'Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia' Posted To ClinicalTrails.Gov; Study Not Yet Recruiting Benzinga

Sep 24, 2021

06:57AM EDT GlycoMimetics' Lead Candidate Data Published In An Online Journal Benzinga

Sep 23, 2021

04:01PM EDT Efficacy And Safety Data For GlycoMimetics' Lead Investigational Drug Uproleselan Published In BLOOD Benzinga

Sep 8, 2021

09:00AM EDT GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference Business Wire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 9, 2021

09:00AM EDT GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

08:05AM EDT GlycoMimetics Q2 EPS $(0.28) Beats $(0.31) Estimate Benzinga

08:04AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

07:42AM EDT GlycoMimetics Q2 Loss/shr $0.28 Vs. Loss/shr $0.32 Prior Year RTTNews

07:30AM EDT GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021 Business Wire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

05:49PM EDT GlycoMimetics Names Harout Semerjian CEO Benzinga

04:15PM EDT GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel King Business Wire

Jul 29, 2021

04:31PM EDT GlycoMimetics to Report Second Quarter Financial Results on August 5, 2021 Business Wire

Jul 26, 2021

09:56AM EDT UPDATE: Roth On GlycoMimetics: Firm Sees 1st Patient Dosed With Uproleselan In An Investigator-Sponsored Trial; Strong Data Supports Upro E-selectin Antagonist In Combo With Chemotherapy To Enhance Efficacy By Mobilizing AML Cancer Cells From Bone Marrow Benzinga

09:56AM EDT Roth Capital Maintains Buy Rating On GlycoMimetics With $15 Price Target Benzinga

Jul 22, 2021

09:15AM EDT GlycoMimetics : Trial Launches To Evaluate Uproleselan Added To Cladribine Plus Low-Dose Cytarabine In AML Patients RTTNews

09:01AM EDT GlycoMimetics Announces Clinicians Have Treated First Patient In Phase 1b/2 Study Evaluating Uproleselan Benzinga

09:00AM EDT Trial Launches to Evaluate GlycoMimetics' Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients Business Wire

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 12, 2021

09:20AM EDT GlycoMimetics Inc. (GLYC) announced that clinicians at University of California Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-nave acute myeloid leukemia or AML. RTTNews

09:09AM EDT GlycoMimetics Initiates Clinical Trial Evaluating Uproleselan In Combination With Venetoclax And Azacitidine RTTNews

09:00AM EDT GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination With Venetoclax and Azacitidine Business Wire

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

May 27, 2021

07:08PM EDT GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference Business Wire

May 26, 2021

09:52AM EDT GLYC: First Patient Dosed In Trial Evaluating Uproleselan As Prophylactic Agent To Reduce Gastrointestinal Toxicities RTTNews

09:01AM EDT GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan For Prevention Of Gastro-Intestinal Toxicity In Autologous Hematopoietic Cell Transplantation Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

May 3, 2021

07:52AM EDT GlycoMimetic Q1 Loss Per Share $0.28 Vs Loss $0.18 Last Year RTTNews

07:35AM EDT GlycoMimetics Q1 EPS $(0.28) Beats $(0.32) Estimate Benzinga

07:30AM EDT GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021 Business Wire

04:13AM EDT Earnings Scheduled For May 3, 2021 Benzinga

Apr 26, 2021

09:00AM EDT GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 Business Wire

Mar 10, 2021

04:37PM EST GlycoMimetics To Present Interim Analysis Of Phase 1b Proof-Of-Concept Study At American Association For Cancer Research Apr. 10, 2021 Benzinga

04:30PM EST GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting Business Wire

Mar 4, 2021

08:41AM EST Apollomics Doses First Patient In Phase 1 Clinical Trial In China Of GlycoMimetics' Uproleselan For Treatment Of AML RTTNews

08:36AM EST Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AML Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

07:37AM EST GlycoMimetics Q4 EPS $(0.32), Inline, Sales $163.00K Miss $200.00K Estimate Benzinga

07:30AM EST GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020 Business Wire

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

04:30PM EST GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences Business Wire

Feb 23, 2021

04:30PM EST GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2 Business Wire

09:10AM EST GlycoMimetics Names Dr. Eric Feldman As Chief Medical Officer Benzinga

09:00AM EST GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer Business Wire

Jan 7, 2021

07:16AM EST GlycoMimetics And Apollomics Announce APL-106 Granted Breakthrough Therapy Designation In China For Treatment Of Acute Myeloid Leukemia Benzinga

07:10AM EST APL-106 (uproleselan) Granted Breakthrough Therapy Designation in GlobeNewswire Inc

Dec 8, 2020

10:16AM EST Roth Capital Maintains Buy on GlycoMimetics, Raises Price Target to $15 Benzinga

Dec 7, 2020

04:32PM EST GlycoMimetics Reports New Supportive Efficacy Data For The Company's Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition Benzinga

04:30PM EST New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition Business Wire

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 5, 2020

06:00PM EST GlycoMimetics' Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model Business Wire

Nov 10, 2020

04:00PM EST GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences Business Wire

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

07:40AM EST GlycoMimetics Q3 Loss Per Share $0.29 Vs Loss $0.31 Last Year RTTNews

07:32AM EST GlycoMimetics Q3 EPS $(0.29) Beats $(0.33) Estimate, Sales $1.00M Benzinga

07:30AM EST GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020 Business Wire

03:33AM EST Earnings Scheduled For November 6, 2020 Benzinga

Nov 4, 2020

01:08PM EST GlycoMimetics Highlights 3 Abstracts Accepted For Oral Presentations, 2 Abstracts For Poster Presentations At American Society Of Hematology Dec. 5-8 Benzinga

01:03PM EST GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition Business Wire

05:14AM EST Mark Lampert Purchased 932,612 Shares of Glycomimetics @ Avg Price: $2.75/Share as per Form 4 Filing on November 3 Benzinga

Oct 30, 2020

09:00AM EDT GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020 Business Wire

Oct 26, 2020

09:08AM EDT GlycoMimetics Reports New Pediatric, Secondary Endpoint Data From Rivipansel Phase 3 RESET Trial Presented At Annual Scientific Conference On Sickle Cell And Thalassemia Meeting Benzinga

09:05AM EDT GlycoMimetics Announces That New Post Hoc Analyses Of The Phase 3 RESET Study RTTNews

09:00AM EDT New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting Business Wire

Oct 7, 2020

04:25PM EDT GlycoMimetics Announces That It Entered Into A Sales Agreement With Cowen & Co. GlycoMinmetics May Offer And Sell Shares Having Offering Price Of Up To $100M Benzinga

Oct 5, 2020

06:14PM EDT After Market Hours: Alteryx, GlycoMimetics, Spartan Energy RTTNews

04:32PM EDT GlycoMimetics Announces FDA Has Granted The Company A Rare Pediatric Disease Designation For Rivipansel For The Treatment Of Sickle Cell Disease In Patients 18 Years Old And Younger Benzinga

04:30PM EDT FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease Business Wire

Sep 8, 2020

04:00PM EDT GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference Business Wire

Sep 4, 2020

09:02AM EDT GlycoMimetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Benzinga

Aug 31, 2020

09:13AM EDT GlycoMimetics Reports New Preclinical Data Showing Uproleselan With Venetoclax/Hypomethylating Agent In Acute Myeloid Leukemia May Prolong Survival Benzinga

09:05AM EDT GlucoMimetics Says Preclinical Data Suggests Uproleselan With Ventoclax/HMA In AML May Prolong Survival In Patients With Acute Myeloid Leukemia Benzinga

09:00AM EDT New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival Business Wire

Jul 31, 2020

12:53PM EDT HC Wainwright & Co. Maintains Buy on GlycoMimetics, Lowers Price Target to $15 Benzinga

08:07AM EDT GlycoMimetics Q2 EPS $(0.32) Beats $(0.38) Estimate Benzinga

08:00AM EDT GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020 Business Wire

04:15AM EDT Earnings Scheduled For July 31, 2020 Benzinga

Jul 24, 2020

09:15AM EDT GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020 Business Wire

Share